# A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

> **NCT05665530** · PHASE1 · COMPLETED · sponsor: **Prelude Therapeutics** · enrollment: 86 (actual)

## Conditions studied

- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Mantle Cell Lymphoma (MCL)
- Richter's Syndrome
- T-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- Marginal Zone Lymphoma
- Myeloid Malignancies
- Acute Myeloid Leukemia (AML)
- Chronic Myelomonocytic Leukemia (CMML)
- Myelodysplastic Syndrome (MDS)
- MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome

## Interventions

- **DRUG:** PRT2527
- **DRUG:** Zanubrutinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05665530
- **Lead sponsor:** Prelude Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-12
- **Primary completion:** 2025-06-12
- **Final completion:** 2026-01-21
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05665530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05665530, "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05665530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*